No abstract available.
Neuroleptic Malignant Syndrome*

We report a patient developed neuroleptic malignant syndrome (NMS) with myoglobulinemic acute renal failure and lithium intoxication due to lithium-olanzapine combination, who was successfully treated by hemodiafiltration. A 34-year-old woman with a 14-year history of bipolar disorder had been treated with lithium-olanzapine during last four days. She was admitted to our hospital for muscular rigidity, hyperthermia and altered consciousness. On admission, rhabdomyolsis was demonstratd by biochemical methods and serum level of lithium was 3.78 mEq/L which was far above toxic level. After the diagnosis of NMS with acute renal failure and lithium intoxication, olanzapine and lithium were discontinued and conservative measures and continuous venovenous hemodiafiltration were instituted. She recovered without any neurologic sequelae.
Female ; Humans ; Neuroleptic Malignant Syndrome

No abstract available.
Levodopa* ; Neuroleptic Malignant Syndrome* ; Parkinson Disease*

Neuroleptic malignant syndrome (NMS) is a fatal complication most often caused by an adverse reaction to neuroleptic or antipsychotic drugs, and is mostly brought out in the initial stage of medication. Late onset NMS after long term intake of neuroleptics is uncommon, and the neurochemical mechanism is undiscovered. We report a patient of late onset NMS after a long term intake of haloperidol who was successfully treated with dantrolene and bromocriptine.
Antipsychotic Agents ; Bromocriptine ; Dantrolene ; Haloperidol ; Humans ; Neuroleptic Malignant Syndrome

Aged ; Humans ; Male ; Neuroleptic Malignant Syndrome ; etiology ; physiopathology ; Parkinson Disease ; drug therapy ; Substance Withdrawal Syndrome

Neuroleptic malignant syndrome and serotonin syndrome share many common clinical features, and the term "Neurotoxic syndrome" can be used when a clear distinction cannot be made between the two. Here we present a case of 19-year-old man who experienced serotonin syndrome caused by sertraline intake, and consecutive neuroleptic malignant syndrome by risperidone. This case suggests that these two syndromes can be concomitantly induced in some patients who are susceptible to these drugs. Clinicians may have to pay close attention to this problem when prescribing drugs to patients who previously showed sensitivity to CNS-acting drugs.
Antipsychotic Agents ; Humans ; Neuroleptic Malignant Syndrome ; Risperidone* ; Serotonin Syndrome ; Sertraline* ; Young Adult

Neuroleptic malignant syndrome and serotonin syndrome share many common clinical features, and the term "Neurotoxic syndrome" can be used when a clear distinction cannot be made between the two. Here we present a case of 19-year-old man who experienced serotonin syndrome caused by sertraline intake, and consecutive neuroleptic malignant syndrome by risperidone. This case suggests that these two syndromes can be concomitantly induced in some patients who are susceptible to these drugs. Clinicians may have to pay close attention to this problem when prescribing drugs to patients who previously showed sensitivity to CNS-acting drugs.
Antipsychotic Agents ; Humans ; Neuroleptic Malignant Syndrome ; Risperidone* ; Serotonin Syndrome ; Sertraline* ; Young Adult

We describe a case of recurrent, life-threatening, catatonic stupor, without evidence of any associated medical, toxic or mental disorder. This case provides support for the inclusion of a separate category of "unspecified catatonia" in the Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM-5) to be used to classify idiopathic cases, which appears to be consistent with Kahlbaum's concept of catatonia as a distinct disease state. But beyond the limited, cross-sectional, syndromal approach adopted in DSM-5, this case more importantly illustrates the prognostic and therapeutic significance of the longitudinal course of illness in differentiating cases of catatonia, which is better defined in the Wernicke-Kleist-Leonhard classification system. The importance of differentiating cases of catatonia is further supported by the efficacy of antipsychotics in treatment of this case, contrary to conventional guidelines.
Antipsychotic Agents ; Catatonia* ; Classification ; Diagnostic and Statistical Manual of Mental Disorders* ; Mental Disorders ; Neuroleptic Malignant Syndrome ; Schizophrenia ; Stupor

Risperidone is a relatively new antipsychotic agent. It is often referred to as 'atypical', because it has a mechanism of action that blocks post synaptic dopamine-2 and serotonin-2 receptors, it is associated with fewer extrapyramidal side effects, it is not yet associated with tardive dyskinesia, and it may have some efficacy on negative symptoms of schizophrenia. In despite of its 'atypical' nature, there are already more than 15 reports of risperidone-induced neuroleptic malignant syndrome. Only one case of risperidone-induced NMS was reported recently in Korea. We report one case of delayed risperidoneinduced neuroleptic malignant syndrome in young male patient and review the related articles.
Humans ; Korea ; Male ; Movement Disorders ; Neuroleptic Malignant Syndrome* ; Receptors, Serotonin, 5-HT2 ; Risperidone ; Schizophrenia

The neuroleptic malignant syndrome(NMS) results primarily from an imbalance of central neurotransmitters and typically occurs after acute or chronic neuroleptic drug use rather than after neuroleptic overdosage. It is a rare and serious iatrogenic syndrome that is characterized by hyperthermia, muscle rigidity, autonomic dysfunctions and altered mental status. We have observed a case of NMS-like state due to depot of chlorpromazine(CPZ) and have experienced symptomatic and supportive treatment, which including body surface cooling, fluid administration, diuretics, and diazepam. So, in order to provide interests with this clinical situation for emergency physician, pathophysiology is discussed with references to the possibility of NMS in our case and symptomatology and managements are also reviewed.
Chlorpromazine* ; Diazepam ; Diuretics ; Emergencies ; Fever ; Muscle Rigidity ; Neuroleptic Malignant Syndrome ; Neurotransmitter Agents